AstraZeneca’s COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

AstraZeneca’s Lung Disease Drug Shows Broad Benefit in Trials

AstraZeneca Plc’s experimental medicine for the deadly lung condition COPD significantly reduced flare-ups for a wide range of patients in trials, boosting the drug’s blockbuster prospects.

AstraZeneca : Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

Tozorakimab showed clinically meaningful benefits across blood eosinophil thresholds Full results published in the New England Journal of Medicine and presented at the European...

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.

AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies

The data suggest the drug, known as 'tozo,' could be competitive with other new COPD treatments, and potentially reach more patients.

It turns out COPD may be a laughing matter after all

Researchers in Türkiye have shown in a small clinical trial that laughter therapy can reduce breathing difficulties in COPD patients.

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials